Cost-effectiveness analysis of savolitinib for locally advanced or metastatic non-small-cell lung cancer with MET mutations
OBJECTIVE To evaluate the cost-effectiveness of savolitinib group versus crizotinib group in first-line treatment of locally advanced or metastatic non-small-cell lung cancer(NSCLC)with mesenchymal-epithelial transition factor(MET)mutations to provide references for healthcare decision-making.METHODS Based upon the clinical trial data,a partitioned sur-vival model was constructed from the perspective of Chinese healthcare system.Total expense,quality-adjusted life-years(QALY)and incremental cost-effectiveness ratio(ICER)of two groups were calculated and annual discount rate was 5％.Single factor sensitivity analysis and probabilistic sensitivity analysis were performed for evaluating the stability of parametric results.RESULTS Total expense of savolitinib group was ¥442 232 and 0.931 QALYs was obtained.Total expense of crizotinib group was ¥322 138 and 0.677 QALYs was obtained.ICER of savolitinib group versus crizotinib group was ¥472 799/QALY.It exceeded the willingness-to-pay threshold of ¥257 094/QALY in China.CONCLUSION From the perspective of Chinese healthcare system,savolitinib is not cost-effectiveness as compared with crizotinib for locally advanced or metastatic NSCLC with MET mutations.
pharmacoeconomicscost-effectiveness analysissavolitinibnon-small-cell lung cancer with MET mutations
NETL
NSTL
万方数据
